医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
10期
1925-1928
,共4页
陈泠希%陈英%陈琼%孙明
陳泠希%陳英%陳瓊%孫明
진령희%진영%진경%손명
曲美他嗪/治疗应用%心肌病 ,酒精性/药物疗法%M eta分析%随机对照试验
麯美他嗪/治療應用%心肌病 ,酒精性/藥物療法%M eta分析%隨機對照試驗
곡미타진/치료응용%심기병 ,주정성/약물요법%M eta분석%수궤대조시험
Trimetazidine/TU%Cardiomyopathy,Alcoholic/DT%Meta-Analysis%Randomized Controlled T rial
【目的】采用Meta分析评价联用曲美他嗪(TMZ)治疗酒精性心肌病(ACM )的有效性。【方法】检索PubMed、MedLine、Clinical Trials、Cochrane临床对照试验中心数据库、CNKI全文数据库、万方医学数据库、维普全文数据库建库至今公开发表的与TMZ治疗ACM 相关的临床试验文献。按照纳入和排除原则进行文献筛选及进行方法学质量评估。采用RevM an 5.2软件进行M eta分析。【结果】共纳入5项研究,288例患者。Meta分析显示:与β受体阻滞剂、血管紧张素转换酶抑制剂(ACEI)、利尿剂、维生素等常规治疗相比,联用TMZ治疗可明显增加6分钟步行距离(WMD=74.53,95% CI 25.55~123.50),明显提高左室射血分数(W M D=5.15,95% C I 2.82~7.49),具有更好的治疗有效性(O R=8.94,95% C I 2.44~32.80)。【结论】联用TMZ可明显改善ACM患者的心功能指标,改善患者生活质量。
【目的】採用Meta分析評價聯用麯美他嗪(TMZ)治療酒精性心肌病(ACM )的有效性。【方法】檢索PubMed、MedLine、Clinical Trials、Cochrane臨床對照試驗中心數據庫、CNKI全文數據庫、萬方醫學數據庫、維普全文數據庫建庫至今公開髮錶的與TMZ治療ACM 相關的臨床試驗文獻。按照納入和排除原則進行文獻篩選及進行方法學質量評估。採用RevM an 5.2軟件進行M eta分析。【結果】共納入5項研究,288例患者。Meta分析顯示:與β受體阻滯劑、血管緊張素轉換酶抑製劑(ACEI)、利尿劑、維生素等常規治療相比,聯用TMZ治療可明顯增加6分鐘步行距離(WMD=74.53,95% CI 25.55~123.50),明顯提高左室射血分數(W M D=5.15,95% C I 2.82~7.49),具有更好的治療有效性(O R=8.94,95% C I 2.44~32.80)。【結論】聯用TMZ可明顯改善ACM患者的心功能指標,改善患者生活質量。
【목적】채용Meta분석평개련용곡미타진(TMZ)치료주정성심기병(ACM )적유효성。【방법】검색PubMed、MedLine、Clinical Trials、Cochrane림상대조시험중심수거고、CNKI전문수거고、만방의학수거고、유보전문수거고건고지금공개발표적여TMZ치료ACM 상관적림상시험문헌。안조납입화배제원칙진행문헌사선급진행방법학질량평고。채용RevM an 5.2연건진행M eta분석。【결과】공납입5항연구,288례환자。Meta분석현시:여β수체조체제、혈관긴장소전환매억제제(ACEI)、이뇨제、유생소등상규치료상비,련용TMZ치료가명현증가6분종보행거리(WMD=74.53,95% CI 25.55~123.50),명현제고좌실사혈분수(W M D=5.15,95% C I 2.82~7.49),구유경호적치료유효성(O R=8.94,95% C I 2.44~32.80)。【결론】련용TMZ가명현개선ACM환자적심공능지표,개선환자생활질량。
[Objective] To evaluate the effectiveness of trimetazidine(TMZ) for the combined treatment of alcoholic cardiomyopathy(ACM) by using Meta‐analysis .[Methods] The published clinical trial articles about TMZ for the treatment of ACM by searching the databases of PubMed ,MedLine ,Clinical Trials ,Cochrane Library ,CNKI ,Wangfang and Weipu .According to enrollment and exclusion principle ,the articles were screened and evaluated by methodological quality assessment .Meta‐analysis was accomplished by RevMan 5 .2 software .[Results] Totally 5 studies(288 patients) were enrolled .Meta‐analysis showed that the combined treatment with TMZ could obviously increase the distance of 6‐minute walk test (6MWT )[weighted mean difference(WMD)=74 .53 ,95% confidence interval(CI) 25 .55 to 123 .50] ,and improve left ventricular ejec‐tion fraction(LVEF)(WMD=5 .15% ,95% CI 2 .82 to 7 .49) ,and had better treatment effectiveness [odds ra‐tio(OR)=8 .94 ,95% CI 2 .44 to 32 .80] in comparison with the convention therapy with beta‐receptor bloc‐ker ,angiotensin converting enzyme inhibitor (ACEI) ,diuretics and vitamins .[Conclusion] The combined treatment with TMZ can obviously improve cardiac function indicators of ACM patients with ACM ,and en‐hance the quality of life .